Compare 10X Genomics Inc (TXG) vs ZIM Integrated Shipping Services Ltd (ZIM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs ZIM Integrated Shipping Services Ltd — how do they compare? 10X Genomics Inc trades at $82.37 (market cap $10.07B), while ZIM Integrated Shipping Services Ltd trades at $30.2 (market cap $3.65B). The key difference: 10X Genomics Inc is far larger — about 2.8× ZIM Integrated Shipping Services Ltd's market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 92 Days and ZIM Integrated Shipping Services Ltd for 27 Days on average.
| TXG | ZIM | |
|---|---|---|
Market Cap | $10.07B | $3.65B |
Volume | 5,657,286 | 1,068,475 |
Sector | Health | Industrials |
52-Week High | $97.74 | $30.51 |
52-Week Low | $11.48 | $12.44 |
Typical Hold Time | 92 Days | 27 Days |
Enterprise Value | $9.59B | $7.32B |
Dividend Yield | — | 20.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
ZIM Integrated Shipping Services trades at $30.31, up 1.07% with a bullish technical signal from moving averages. The stock shows mixed fundamentals with declining revenue from $6.9B in 2025 to $6.4B in 2026 and net income dropping from $479M to $139M, though Q2 2026 earnings beat expectations. Recent news highlights a potential $35 per share acquisition offer from Hapag-Lloyd pending Israeli government approval, creating significant uncertainty.
The investment outlook balances acquisition upside against operational challenges. While valuation metrics appear reasonable (P/E 26.31, P/S 0.57), declining profitability and the uncertain merger outcome present substantial risk. Analyst sentiment remains cautious with no buy ratings, reflecting concerns about the company's standalone prospects if the acquisition fails to materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About ZIM Integrated Shipping Services Ltd
ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →
